- Press Release Distribution

Internationally recognized thoracic oncologist Dr. Taofeek K. Owonikoko named Executive Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Physician-scientist will lead the NCI-designated comprehensive cancer center through continued growth and major expansion

Internationally recognized thoracic oncologist Dr. Taofeek K. Owonikoko named Executive Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
( University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, and University of Maryland Medical Center (UMMC) President and CEO Bert W. O’Malley, MD, announced today that Taofeek K. Owonikoko, MD, PhD, a distinguished physician-scientist with a global reputation in thoracic oncology, has been appointed Executive Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). Dr. Owonikoko will join the UMSOM faculty as the Marlene and Stewart Greenebaum Professor in Oncology in the Department of Medicine and Executive Director of the UMSOM Program in Oncology.  He will also become Chief of Service at UMMC. As the lead oncologist for both UMMC and UMSOM, he will assume the positions of Senior Associate Dean for Cancer Programs at UMSOM and Associate Vice President for Cancer Programs at the University of Maryland, Baltimore (UMB).  

He will begin his tenure in January 2024, taking over from Kevin J. Cullen, MD, who is stepping down as director after 20 years. Dr. Cullen will continue to teach medical students and treat patients at the cancer center.

Dr. Owonikoko, a thoracic medical oncologist who specializes in treating patients with lung cancer, was selected to take the helm of the National Cancer Institute (NCI)-designated comprehensive cancer center at the University of Maryland Medical Center (UMMC) after an extensive national search by a search committee led by Christine Lau, MD, MBA, the Dr. Robert W. Buxton Professor and Chair of the Department of Surgery at UMSOM and Surgeon-in-Chief at UMMC, and Graeme Woodworth, MD, the Howard M. Eisenberg, MD Distinguished Professor and Chair of Neurosurgery.

Leader in Translational Research

Dr. Owonikoko is board-certified in medical oncology, hematology, and internal medicine. His research has focused on the discovery of pre-clinical biomarkers in small cell lung cancer and other solid tumors and translating promising laboratory findings into groundbreaking clinical trials through collaboration with academic and industry partners.

He is internationally regarded as one of the preeminent physician-scientists in cancer research.  He has secured substantial grant funding from the National Institutes of Health (NIH), the Department of Defense (DOD), industry partners and private foundations. Presently, Dr. Owonikoko is the recipient of an NIH R01 grant supporting innovative research into new treatments for small cell lung cancer. Notably, his laboratory's fundamental discoveries have paved the way for multiple clinical trials at both institutional and national levels.  With a significant h-index of 83 (an author-level metric that measures productivity and citation impact), he has made substantial contributions to the field of oncology, authoring more than 250 original articles in high-impact scientific journals, with over 44,000 citations. Dr. Owonikoko currently serves as an elected board member and treasurer-elect of the prestigious American Society of Clinical Oncology (ASCO), the leading society of oncologists globally. 

Extraordinary Track Record of Success

“We are very excited to welcome Dr. Owonikoko to the University of Maryland School of Medicine faculty. He has an extraordinary track record of academic and clinical success and is widely regarded as an innovative leader in translational research and a strategic collaborator,” said UMSOM Dean Gladwin, who is also Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor at UMSOM.  “At the same time, we are deeply grateful to Dr. Cullen for his tireless commitment and leadership in building the UMGCCC into one of the great discovery-based cancer centers in the nation.”

Dr. O’Malley added: “Over the last two decades, Dr. Cullen has led our cancer center to unprecedented growth and left us poised to reach even greater heights in the years to come. We now look forward to leveraging Dr. Owonikoko’s passion for advancing clinical innovations and groundbreaking research to further position Greenebaum among the nation’s top cancer institutions.”

Mohan Suntha, MD, MBA, President and CEO of the University of Maryland Medical System (UMMS) and a radiation oncologist, said:  “Dr. Owonikoko has earned a stellar reputation as a collaborative and visionary leader with demonstrated ability to substantially grow research and clinical programs of excellence.  As an academic cancer center, UMGCCC is a vital resource for cancer patients treated at hospitals within our medical system. I am particularly enthusiastic about the key role Dr. Owonikoko will play in expanding access to state-of-the-art clinical trials.”

Made Cancer Care More Accessible to Patients

Currently, Dr. Owonikoko serves as Chief of the Division of Hematology/Oncology and the Stanley M. Marks – Oncology Hematology Associates (OHA) Endowed Chair in Hematology/Oncology Leadership at the University of Pittsburgh School of Medicine. He is also Associate Director for Translational Research and Co-Leader of the Cancer Therapeutics Program at the UPMC Hillman Cancer Center where he has been instrumental in steering translational research, developing innovative therapeutics and expanding clinical care initiatives.

As a key member of the Hillman Cancer Center leadership team, he has helped to make cancer clinical trials more accessible to patients, particularly those in underserved communities, through the large network of outpatient practices, with more than 70 locations in Pennsylvania, Ohio, New York, and Western Maryland. Dr. Owonikoko is also committed to fostering the growth and development of the next generation of clinical and research leaders through robust training and mentoring programs. 

Previously, he served as Professor and Vice Chair in the Department of Hematology and Medical Oncology at the Emory University School of Medicine and its Winship Cancer Institute.

Dr. Lau, who co-chaired the search committee, said, "The team really worked hard to get the right leader, and we feel strongly that we did. I am excited to support Dr. Owonikoko as we advance cancer care at SOM, UMMC, and across the System."

Dr. Owonikoko said he was "greatly honored and humbled to be selected as the next director of UMGCCC. My gratitude goes to the search committee members and the leadership team across UMB and UMMS for this incredible opportunity. I look forward to joining this vibrant and collegial community and working together to actualize the strategic vision to bring UMGCCC to greater heights by building on the solid foundation laid over the past two decades, through the strong work of my predecessor, Dr. Kevin Cullen, and the entire faculty and staff." 

Dr. Cullen commented about his successor: “Taofeek is a superb clinician-scientist with extensive leadership experience. His recent work at two NCI-designated cancer centers will serve him well as he leads UMGCCC through its next phase of growth. I believe the Greenebaum Comprehensive Cancer will thrive under his direction, and I am delighted that he has chosen to come to Baltimore.  As I step down after 20 years, I know the cancer center is in excellent hands.” 

Cheryl L. Knott, PhD, co-leader of UMGCCC’s population science program and associate director of community outreach and engagement who served on the search committee, said she appreciates Dr. Owonikoko’s approach and vision for his new position. “The clinical and scientific resume that he brings to the table speaks for itself. However, I also appreciated the humility with which he approached the UMGCCC opportunity, his thoughtful views about diversity, equity and inclusion, and his patient-centered approach,” Dr. Knott said. “This speaks to an alignment with our mission and values at UMGCCC as a comprehensive cancer center with a strong orientation toward the community that we serve.”

An NCI-Designated Comprehensive Cancer Center

The cancer center – a joint entity of UMSOM and UMMC – is one of only 56 NCI-designated comprehensive cancer centers throughout the country and one of two centers in Maryland. UMGCCC treats just over 3,000 new patients annually with more than 59,000 outpatient visits and 1,100 inpatient admissions each year. The center’s research funding has increased dramatically in recent years, now totaling $122 million. UMGCCC serves as the academic hub for cancer centers at affiliated hospitals within the 11-hospital University of Maryland Medical System.

Patient volume at UMGCCC has also grown significantly in recent years, and construction is underway on a 12-story building – the Roslyn and Leonard Stoler Center for Advanced Medicine – that will be the new home of the cancer center when it is completed in 2026. The expansion will help UMGCCC meet the growing need for complex cancer care, including cutting-edge cellular immunotherapies and personalized treatments tailored to a patient’s individual cancer and genetic profile.

The cancer center’s reach extends well beyond its walls. Not only do UMGCCC physicians and scientists mentor West Baltimore middle and high school students for potential STEM-related careers through the UMB Cure Scholars Program and other internship programs, UMGCCC also offers patient education and screening initiatives to communities throughout Maryland. These include free cancer screenings through the community-based Baltimore City Cancer Program, with a focus on eliminating disparities in cancer care.

“We are thrilled to have Dr. Owonikoko as our new leader.  He is a world class physician-scientist who is ideally suited to carry on the tremendous legacy of Dr. Cullen,” said Michael Greenebaum, President, Greenebaum Enterprises and Vice Chair, UMSOM Board of Visitors, whose parents, Marlene and Stewart Greenebaum, gave the founding gift for the UM Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) in 1994. “We are confident that he will take the UM Greenebaum Comprehensive Cancer Center to even greater heights of excellence in both research and patient care. On behalf of our entire family, we want to express our deepest gratitude to Dr. Cullen for his outstanding leadership over the past two decades.  We will always have the greatest admiration for him as a close friend and colleague,” he added.

Personal Background and Professional Leadership

Born in Nigeria, Dr. Owonikoko earned his primary medical degree in 1991 from Obafemi Awolowo University in Nigeria, a PhD degree in Anatomic Pathology from Heinrich Heine University in Duesseldorf, Germany in 2001, and later a Master of Science degree in Clinical Research degree from the James T. Laney School of Graduate Studies at Emory University.

In addition to his leadership role at ASCO, Dr. Owonikoko is affiliated with several professional organizations, including the American Association for Cancer Research (AACR), the Society for Immunotherapy of Cancer, and the International Association for the Study of Lung Cancer. He has also served as an ad hoc reviewer on NIH and DOD Study Sections for the past 11 years. 

He currently is a chartered member for the NCI Clinical Oncology Study Section.  Additionally, he is an editorial board member for several highly regarded academic journals, including Cancer, Frontiers in Oncology, Journal of Thoracic Disease and Translational Lung Cancer Research. 

He has received numerous awards, including the Michaele C. Christian Oncology Development Lectureship and Award from the NCI in 2020, the Heine Hansen Award for Small Cell Lung Cancer from the International Association for the Study of Lung Cancer (IASLC), and the Leadership Development Program award from ASCO.

“I am very excited to bring a servant leadership style to fully harness the depth of scientific expertise at UMB and the sister campuses of the University System of Maryland, to impact the diverse communities served by UMMC and the other components of the UMMS network of hospitals across the state of Maryland,” Dr. Owonikoko added. “I am confident that the outstanding research expertise, excellent patient care and deep commitment to education and the community that define UMGCCC, will help us realize the vision set by the management team to be a leader among its peer NCI-designated comprehensive cancer centers.”

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding.  As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies.  In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2023, the UM School of Medicine is ranked #10 among the 92 public medical schools in the U.S., and in the top 16 percent (#32) of all 192 public and private U.S. medical schools.  The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit

About the University of Maryland Medical Center

The University of Maryland Medical Center (UMMC) is comprised of two hospital campuses in Baltimore: the 800-bed flagship institution of the 11-hospital University of Maryland Medical System (UMMS) and the 200-bed UMMC Midtown Campus. Both campuses are academic medical centers for training physicians and health professionals and for pursuing research and innovation to improve health. UMMC's downtown campus is a national and regional referral center for trauma, cancer care, neurosciences, advanced cardiovascular care, and women's and children's health, and has one of the largest solid organ transplant programs in the country. All physicians on staff at the downtown campus are clinical faculty physicians of the University of Maryland School of Medicine. The UMMC Midtown Campus medical staff is predominantly faculty physicians specializing in a wide spectrum of medical and surgical subspecialties, primary care for adults and children and behavioral health. UMMC Midtown has been a teaching hospital for 140 years and is located one mile away from the downtown campus. For more information, visit

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is a National Cancer Institute-designated comprehensive cancer center in Baltimore. The center is a joint entity of the University of Maryland Medical Center and University of Maryland School of Medicine. It offers a multidisciplinary approach to treating all types of cancer and has an active cancer research program. It is ranked among the top cancer programs in the nation.


[Attachments] See images for this press release:
Internationally recognized thoracic oncologist Dr. Taofeek K. Owonikoko named Executive Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center


Meat taxes and other livestock emissions regulations could be feasible, acceptable and effective, argue climate researchers

Meat taxes and other livestock emissions regulations could be feasible, acceptable and effective, argue climate researchers. #### Article URL: Article Title: High ‘steaks’: Building support for reducing agricultural emissions Author Countries: Germany, UK Funding: This work was financially supported by the Robert Bosch foundation (Junior Professorship grant to LM) The funder had no role in study design, data collection and analysis, decision to publish, ...

Accelerated radiation treatment could reduce head and neck cancer patient burden in low- and middle-income countries

SAN DIEGO, October 2, 2023 — A type of head and neck cancer predominantly diagnosed in people who reside in low- and middle-income countries may be treated effectively with fewer, but higher doses of radiation, a large new international study suggests. The study – a randomized phase III clinical trial involving 10 countries across four continents – found delivering a course of radiation in 20 rather than 33 treatment sessions was just as effective at controlling cancer for patients with alcohol and tobacco-related, locally advanced disease, without increasing side ...

October issues of American Psychiatric Association journals look at factors influencing depression and PTSD, guidance on handling drugs laced with fentanyl, and more

The latest issues of three of the American Psychiatric Association’s journals, The American Journal of Psychiatry, Psychiatric Services and The American Journal of Psychotherapy are now available online. The October issue of The American Journal of Psychiatry is focused on research devoted to understanding factors influencing depression, PTSD, and suicidal behavior. Highlights include: Genetic Contribution to the Heterogeneity of Major Depressive Disorder: Evidence From a Sibling-Based Design Using Swedish National Registers. Maternal Perinatal Stress Trajectories and Negative Affect and Amygdala Development in Offspring. Networks of Neurodevelopmental Traits, Socioenvironmental ...

Men with metastatic prostate cancer live longer thanks to new drugs

Men with metastatic prostate cancer live longer thanks to new drugs
Survival rates for men with metastatic prostate cancer have increased by an average of six months, something which coincides with the gradual introduction of ‘dual treatment’ since 2016. This is according to a register study of all Swedish men diagnosed between 2008 and 2020. The results are published in the medical journal JAMA Network open. Dual treatment means that patients receive both standard hormone therapy (GnRH therapy) and chemotherapy or androgen receptor blockers. Research has previously shown that men receiving this treatment live approximately one year longer than those receiving GnRH treatment alone. “Dual treatment for men with newly diagnosed metastatic ...

A more effective experimental design for engineering a cell into a new state

A strategy for cellular reprogramming involves using targeted genetic interventions to engineer a cell into a new state. The technique holds great promise in immunotherapy, for instance, where researchers could reprogram a patient’s T-cells so they are more potent cancer killers. Someday, the approach could also help identify life-saving cancer treatments or regenerative therapies that repair disease-ravaged organs. But the human body has about 20,000 genes, and a genetic perturbation could be on a combination of genes or on any of the over 1,000 transcription factors that regulate the genes. ...

How the hippocampus distinguishes true and false memories

Let’s say you typically eat eggs for breakfast but were running late and ate cereal. As you crunched on a spoonful of Raisin Bran, other contextual similarities remained: You ate at the same table, at the same time, preparing to go to the same job. When someone asks later what you had for breakfast, you incorrectly remember eating eggs. This would be a real-world example of a false memory. But what happens in your brain before recalling eggs, compared to what would happen if you correctly recalled cereal? In a paper published in Proceedings ...

Drier savannas, grasslands store more climate-buffering carbon than previously believed

Photos Savannas and grasslands in drier climates around the world store more heat-trapping carbon than scientists thought they did and are helping to slow the rate of climate warming, according to a new study.   The study, published online Oct. 2 in Nature Climate Change, is based on a reanalysis of datasets from 53 long-term fire-manipulation experiments worldwide, as well as a field-sampling campaign at six of those sites.   Twenty researchers from institutions around the globe, including two at the University of Michigan, looked at where and why fire has changed the amount of carbon stored in topsoil. They found that within savanna-grassland regions, ...

Ancient architecture inspires a window to the future

Ancient architecture inspires a window to the future
A centuries-old technique for constructing arched stone windows has inspired a new way to form tailored nanoscale windows in porous functional materials called metal-organic frameworks (MOFs). The method uses a molecular version of an architectural arch-forming “centring formwork“ template to direct the formation of MOFs with pore windows of predetermined shape and size.[1]. New MOFs designed and made in this way range from narrow-windowed materials with gas separation potential to larger-windowed structures with potential medical applications due to their excellent oxygen-adsorption capacity. “One of the most challenging ...

Climate and human land use both play roles in Pacific island wildfires past and present

Climate and human land use both play roles in Pacific island wildfires past and present
DALLAS (SMU) – It’s long been understood that human settlement contributes to conditions that make Pacific Islands more susceptible to wildfires, such as the devastating Aug. 8 event that destroyed the Maui community of Lahaina. But a new study from SMU fire scientist Christopher Roos published in the journal Nature Ecology and Evolution shows that climate is an undervalued part of the equation. Roos, SMU environmental archaeologist and professor of anthropology, traveled with his team to the Sigatoka ...

DeepMB: a deep learning framework for high-quality optoacoustic imaging in real-time

Researchers at Helmholtz Munich and the Technical University of Munich have made significant progress in advancing high-resolution optoacoustic imaging for clinical use. Their innovative deep-learning framework, known as DeepMB, holds great promise for patients dealing with a range of illnesses, including breast cancer, Duchenne muscular dystrophy, and inflammatory bowel disease. Their findings have been now published in Nature Machine Intelligence. In order to understand and detect diseases scientists and medical staff often rely on imaging methods such as ultrasound or X-ray. However, ...


Nanoscale topcoat can turbocharge supported gold nanoparticle catalysts

Beyond the ink: Painting with physics

Only 9 percent of older Americans were vaccinated against RSV before the disease hit this fall and winter

Evolution-capable AI promotes green hydrogen production using more abundant chemical elements

In wake of powerful cyclone, remarkable recovery of Pacific island’s forests

PSU study sheds light on 2020 extreme weather event that brought fires and snow to western US

Rice physicist earns NSF CAREER Award to revolutionize quantum technology

Mining the treasures locked away in produced water

Minoritized groups face high anxiety when taking part in research experiments

Orcas demonstrating they no longer need to hunt in packs to take down the great white shark

Scientists discover a novel vehicle for antibiotic resistance

Large-scale study explores link between smoking and DNA changes across six racial and ethnic groups

EU funding for outstanding early-career researcher Pieter Gunnink

Associate Professor Ron Korstanje, Ph.D., of The Jackson Laboratory named Evnin Family Chair

Researchers create coating solution for safer food storage

An overgrowth of nerve cells appears to cause lingering symptoms after recurrent UTIs

New findings on the immune system

Most smokers in England wrongly believe vaping is at least as harmful as smoking

New antibodies target “dark side” of influenza virus protein

Fred Hutch announces 2024 Harold M. Weintraub Graduate Student Award recipients

New academic journal on artificial intelligence launched

UMaine researchers use GPS-tracked icebergs in novel study to improve climate models

A mental process that leads to putting off an unpleasant task

The role of history in how efficient color names evolve

AI outperforms humans in standardized tests of creative potential

Study results show 25% of pregnant people are not getting enough omega-3 fatty acids from their diet or dietary supplements

Cleveland Clinic researchers uncover how virus causes cancer, point to potential treatment

SLU professor studies link between adversity, psychiatric and cognitive decline

Warwick to benefit from £2.5 million funding into “phenomenal” metamaterials

More schooling is linked to slowed aging and increased longevity

[] Internationally recognized thoracic oncologist Dr. Taofeek K. Owonikoko named Executive Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Physician-scientist will lead the NCI-designated comprehensive cancer center through continued growth and major expansion